Navigation Links
NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
Date:4/22/2009

New Collaboration with Leading Researchers having Clinical Experience with Antimicrobials that are Biological Basis for Aganocide Compounds

EMERYVILLE, Calif., April 22 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a mid-stage biopharmaceutical company developing first-in-class, potent, well-tolerated products to treat and prevent a wide range of infections with low chance of developing drug resistance, today announced an exclusive agreement with Professors Markus Nagl M.D. and Waldemar Gottardi, Ph.D. of the Medical University of Innsbruck, Austria. The agreement was entered into to advance the development of NovaBay's Aganocide compounds by integrating extensive and on-going clinical work at the university with NovaBay's development program.

Professors Gottardi and Nagl have conducted extensive clinical research and have patented and published widely for many years on the use of N-chlorotaurine (NCT), a natural antimicrobial produced by the body's white blood cells. NovaBay's Aganocide compounds are synthetic analogs of NCT that maintain or enhance the biological activity of the natural compound while adding pharmaceutically acceptable stability. Professors Gottardi and Nagl have pioneered the exploratory use of NCT compounds in humans in a number of indications that overlap with and even go beyond those for which NovaBay's Aganocide compounds are currently being developed.

Under the terms of the agreement, NovaBay will fund ongoing research in the laboratories of Professors Gottardi and Nagl at the Medical University of Innsbruck and NovaBay will have access to past and future data generated in human clinical trials by Professors Nagl, Gottardi and their collaborators. These data are expected to support many of the indications being pursued by NovaBay and its partners. For instan
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, received official notification from the European Patent Office ... patent supporting its iSONEP™ and ASONEP™ programs. ... No. 2087002, claims compositions of matter related to ... compounds, iSONEP and ASONEP. Sonepcizumab is an antibody ...
(Date:10/20/2014)... NEW YORK and RALEIGH, N.C., Oct. 20, ... the Hereditary Neuropathy Foundation (HNF), both philanthropies, announced ... develop drug candidates for the treatment of the ... BioPontis Alliance announced its alliance model ... is a first demonstration of a collaborative model ...
(Date:10/19/2014)... 19, 2014 Große Pharmafirmen ... Das Problem dabei ist, dass große Pharmafirmen nicht ... zu teilen. Es war deshalb nicht ... uns umso mehr, dass es uns gelungen ist! ... Kühlketten aufzuschreiben - mit einem Vorbehalt - einige ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... WASHINGTON, June 8, 2011 /PRNewswire/ -- A ... (AUA) Annual Meeting shows the less-invasive Pro-Vas® occlusion as ... The clinical study results were presented by Douglas ... AUA Annual Meeting. The AUA meeting is the world,s ...
... 2011 On June 7, 2011, Vycor Medical, Inc. ... in Units comprising Preferred Shares and Warrants (the "Units") ... pursuant to the terms of separate Series C Convertible ... of the Investors. This sale is an initial closing ...
Cached Medicine Technology:Phase I Pro-Vas® Effectiveness Study Presented at AUA Meeting 2Vycor Medical, Inc. Completes Equity Capital Raise 2Vycor Medical, Inc. Completes Equity Capital Raise 3
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
(Date:10/19/2014)... 2014 Hastings and Hastings, a Phoenix ... service throughout the greater Phoenix area and across Arizona ... regard to catastrophic automobile accidents. Statistics have indicated a ... throughout Arizona. As such, Hastings and Hastings has seen ... for those who have been injured through no fault ...
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular ... of bamboo deckings . Moreover, the company has ... are now available at deeply discounted rates. , ... to overstate the significance of online business nowadays. Thus, ... The company’s workers are striving to deliver both value ...
(Date:10/19/2014)... This report provides comprehensive information ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ... on late-stage and discontinued projects. , Partial Seizures ...
(Date:10/19/2014)... Recently, Top10BestSEOHosting.com has unveiled its newest hosting ranking ... are the best VPS hosting suppliers in the ... method of partitioning a physical server computer into ... and capabilities of running on someone’s own dedicated ... attention to VPS products and related suppliers. ...
Breaking Medicine News(10 mins):Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2
... wellbeing in rich countries might depend more on reductions in ... study published today on bmj.com . , Poorer ... But a recent UNICEF report detailing 40 indicators of ... fared worse than in any of the other rich countries. ...
... (NYSE: WPI ), a leading specialty pharmaceutical,company, ... 48, as Senior,Vice President and Chief Financial Officer. ... 20 years of executive,pharmaceutical experience in finance, operations, ... Chief Financial Officer for Watson,Mr. Durand will be ...
... of families with deployed Service members ... ... to the Oregon National Guard,s Emergency Relief fund, which,will support the needs of ... "TriWest made the contribution with the hope that we can make a,difference in ...
... Use of ABILIFY in Patients Ages 10 to 17 ... ... PRINCETON, N.J., Nov. 15 ,Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company ... for filing and granted a Priority Review to the supplemental New,Drug Application ...
... alternative for patients with erosive gastroesophageal reflux disease ... (GERD) who cannot swallow ... of Wyeth (NYSE: WYE ), announced today that the,U.S. ... Delayed-Release Oral Suspension, a new addition,to the Protonix family of ...
... Memphis PGA Tour Stop ... Jude, MEMPHIS, Tenn., Nov. 15 Stanford Financial Group CFO,James ... joined Tony,Thomas from St. Jude and Laurie Tucker, Senior Vice President ... from the,inaugural Stanford St. Jude Championship. The donation from the 2007 ...
Cached Medicine News:Health News:Low standards of child well-being linked to greater income inequality 2Health News:Watson Names Mark Durand Chief Financial Officer 2Health News:TriWest Contributes $30,000 to Oregon National Guard Fund 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 2Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 3Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 4Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 5Health News:ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration 6Health News:Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension 2Health News:Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension 3Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 2Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 3Health News:Stanford St. Jude Championship Presents $1.76 Million Donation To St. Jude Children's Research Hospital(R) 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: